Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials

類似資料

• Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
  著者:: Adam R. Wolfe, 等
  出版事項: (2020-07-01)
• Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
  著者:: Wolfe, Adam R., 等
  出版事項: (2020)
• Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research
  著者:: Cloyd, Jordan M, 等
  出版事項: (2020)
• Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
  著者:: Hamad, Ahmad, 等
  出版事項: (2021)
• National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016
  著者:: Aquina, Christopher T., 等
  出版事項: (2021)